Abstract
Epidemiological studies associate obesity with onset of asthma, especially in obese children, suggesting obesity as the risk factor for asthma. Obesity-induced chronic inflammation has been implicated in the lung inflammation, yet specific mediators and mechanisms are lacking. Obesity is associated with increased expression of 5-lipoxygenase (5-LO) pathway and increased Leukotrienes (LTs) production has been observed in obese asthma patients. However, the precise mechanism that predisposes lungs inflammation in obese is not clearly understood. This article discusses the production and regulation of LTs in obese individuals and presents probable mechanisms regarding the role of LTs in lung inflammation that may lead to obesity-induced asthma. Leukotrienes are well known mediators of asthma but their role in obesity-induced asthma is not clearly understood and thus needs further research. Since efficient antagonists and inhibitors of 5-LO pathways are known, understanding of molecular mechanism of LTs, especially Cysteinyl-LTs, in obesity-induced asthma could lead to optimal treatment regimens for the prevention and treatment of asthma in obese individuals.
Keywords: Adipokines, asthma, cysteinyl leukotrienes, lung inflammation, obesity.
Current Molecular Medicine
Title:Cysteinyl Leukotrienes (CysLTs): Role in Obesity-Induced Asthma
Volume: 15 Issue: 7
Author(s): U.C.S. Yadav
Affiliation:
Keywords: Adipokines, asthma, cysteinyl leukotrienes, lung inflammation, obesity.
Abstract: Epidemiological studies associate obesity with onset of asthma, especially in obese children, suggesting obesity as the risk factor for asthma. Obesity-induced chronic inflammation has been implicated in the lung inflammation, yet specific mediators and mechanisms are lacking. Obesity is associated with increased expression of 5-lipoxygenase (5-LO) pathway and increased Leukotrienes (LTs) production has been observed in obese asthma patients. However, the precise mechanism that predisposes lungs inflammation in obese is not clearly understood. This article discusses the production and regulation of LTs in obese individuals and presents probable mechanisms regarding the role of LTs in lung inflammation that may lead to obesity-induced asthma. Leukotrienes are well known mediators of asthma but their role in obesity-induced asthma is not clearly understood and thus needs further research. Since efficient antagonists and inhibitors of 5-LO pathways are known, understanding of molecular mechanism of LTs, especially Cysteinyl-LTs, in obesity-induced asthma could lead to optimal treatment regimens for the prevention and treatment of asthma in obese individuals.
Export Options
About this article
Cite this article as:
Yadav U.C.S., Cysteinyl Leukotrienes (CysLTs): Role in Obesity-Induced Asthma, Current Molecular Medicine 2015; 15 (7) . https://dx.doi.org/10.2174/1566524015666150831130954
DOI https://dx.doi.org/10.2174/1566524015666150831130954 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Parthenolide in Intracellular Signalling Processes: Review of Current Knowledge
Current Signal Transduction Therapy Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews Physiology and Pharmacology of the Vanilloid Receptor
Current Neuropharmacology The Effect of First-in-Class Small Molecule RhoA Inhibitor, HL07, on the Phenylephrine-induced Artery Contraction
Current Pharmaceutical Design Subject Index to Volume 3
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents A Review of Flavonoids from Cassia Species and their Biological Activity
Current Pharmaceutical Biotechnology Therapeutic Potential of Natural Products in Parkinson’s Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Advances in the Development of Bradykinin Receptor Ligands
Current Topics in Medicinal Chemistry Therapeutic Potential of Natural Products from Terrestrial Plants as TNF-α Antagonist
Current Topics in Medicinal Chemistry Dietary Assumption of Plant Polyphenols and Prevention of Allergy
Current Pharmaceutical Design Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Current Pharmaceutical Design The Discovery and Development of Drug Combinations for the Treatment of Various Diseases from Patent Literature (1980-Present)
Current Topics in Medicinal Chemistry Neuromodulatory and Anti-Inflammatory Ingredient for Sensitive Skin: In Vitro Assessment
Inflammation & Allergy - Drug Targets (Discontinued) Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Biomarkers of Immunity and Inflammation for use in Nutrition Interventions: International Life Sciences Institute European Branch Work on Selection Criteria and Interpretation
Endocrine, Metabolic & Immune Disorders - Drug Targets Perinatal Events Affecting the Onset of Allergic Diseases
Current Drug Targets - Inflammation & Allergy Investigation of 5-HT<sub>3A</sub> Receptor Gene Expression in Peripheral Blood Mononuclear Cells of Individuals who had been Exposed to Air Pollution
Inflammation & Allergy - Drug Targets (Discontinued) Adenosine Receptor Ligands-Recent Developments Part I. Agonists
Current Medicinal Chemistry Adverse Reactions and Pathogen Safety of Intravenous Immunoglobulin
Current Drug Safety GM-CSF and Dendritic Cells in Allergic Airway Inflammation: Basic Mechanisms and Prospects for Therapeutic Intervention
Current Drug Targets - Inflammation & Allergy